Kaposi’s sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi’s sarcoma (KS). KSHV infection is endemic in sub-Saharan Africa where KS is nowadays the most common malignancy, due to widespread infection with KSHV and human immunodeficiency virus (HIV). Importantly, KS also occurs in HIV-negative individuals. Researchers at the University of Helsinki, Finland, have discovered that activation of the DNA damage response in the early stages of KS development functions as an anti-cancer barrier also in virus induced malignancies.
Recent findings suggest that DNA damage checkpoints become activated in early stages of human tumorigenesis, leading to growth arrest or apoptosis and thereby hindering tumor progression. DNA hyper-replication triggered by oncogenes can induce cellular senescence, which together with the oncogene-induced DNA damage checkpoint function as an early anti-cancer barrier. The findings by the research group of Päivi Ojala, Ph.D., (University of Helsinki) demonstrate that the DNA damage checkpoint is activated during the initial stages of KSHV infection and KS tumorigenesis and this can confer a barrier to tumorigenesis also in virus induced cancers.
The study will be published 28.9.2007 in Public Library of Science (PLoS) Pathogens.
KSHV displays two patterns of infection: latent and lytic phase. During latency, only a restricted set of viral genes is expressed. The KSHV genome encodes several homologues of cellular proteins, which engage cellular signaling pathways, govern cell proliferation and modulate apoptosis. The results of this study demonstrate that one of the viral latent proteins, viral cyclin, which is a homolog of cellular D-type cyclins, induces replicative stress in endothelial cells, which leads to senescence and activation of the DNA damage response.
To support the finding early stage lesions of clinical KS specimens were analysed in the study. The results demonstrate that DNA damage checkpoint is activated in early, but not late stage lesions of clinical KS specimens. During the course of infection, the KSHV infected cells may be imposed to overcome this checkpoint, and oncogenic stress elicited by the expression of the viral cyclin may further contribute to the induction of genomic instability and malignant transformation.
Source: University of Helsinki
Related stories:
Sunburn alert: UVB does more damage to DNA than UVA
As bombs burst in air this July 4, chances are that sunburn will be the red glare that most folks see – and feel. But unfortunately, even when there is no burn, the effects of the sun's ultraviolet (UV) rays can have deadly consequences.
Life-extending protein can also have damaging effects on brain cells
Proteins widely believed to protect against aging can actually cause oxidative damage in mammalian brain cells, according to a new report in the July
Cell Metabolism, a publication of Cell Press. The findings suggest that the proteins can have both proaging and protective functions, depending on the circumstances, the researchers said.
New protein that repairs DNA under extreme conditions
Mild environmental conditions are a prerequisite for life. Strong acids or dissolved metallic salts in high concentrations are detrimental to both humans and to simpler life forms, such as bacteria. Such conditions destroy proteins, ensuring that all biological functions in the cells come to a standstill. So what do we find at the limits of hostile conditions where we still find life? Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig (Germany) have joined up with colleagues from Spain and Great Britain to identify an enzyme that requires acids and dissolved metals in order to function. The team describes its findings regarding the extreme protein of the archaebacterium Ferroplasma acidiphilum in the latest online edition of the renowned US research journal
PNAS.
Refusal of suicide order: Why tumor cells become resistant
Cells with irreparable DNA damage normally induce programmed cell death, or apoptosis. However, this mechanism often fails in tumor cells so that transformed cells are able to multiply and spread throughout the body. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered a possible cause of this failure. Tumor cells simply degrade a protein that triggers apoptosis in the case of DNA damage. Blocking this protein degradation might set apoptosis back in operation and, thus, increase the effectiveness of radiotherapy or chemotherapy. The researchers have now published their results in
Nature Cell Biology.
UC researchers find new ways to regulate genes, reduce heart damage
Researchers at the University of Cincinnati (UC) are looking for ways to reduce or prevent heart damage by starting where the problem often begins: in the genes.
Researchers find an evolutionarily preserved signature in the primate brain
Researchers from Uppsala University, Karolinska Institute, and the University of Chicago, have determined that there are hundreds of biological differences between the sexes when it comes to gene expression in the cerebral cortex of humans and other primates. These findings, published June 20th in the open-access journal
PLoS Genetics, indicate that some of these differences arose a very long time ago and have been preserved through the evolution of primates. These conserved differences constitute a signature of sex differences in the brain.
Researchers find an evolutionarily preserved signature in the primate brain
Researchers have determined that there are hundreds of biological differences between the sexes when it comes to gene expression in the cerebral cortex of humans and other primates. These findings, published June 20th in the open-access journal
PLoS Genetics, indicate that some of these differences arose a very long time ago and have been preserved through evolution. These conserved differences constitute a signature of sex differences in the brain.
MIT researchers see alternative to common colorectal cancer drug
A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.